Cohance Lifesciences rises on getting nod to make $10 million investment in NJ Bio Inc
Cohance Lifesciences is currently trading at Rs. 549.70, up by 3.50 points or 0.64% from its previous closing of Rs. 546.20 on the BSE.
The scrip opened at Rs. 549.05 and has touched a high and low of Rs. 557.70 and Rs. 541.00 respectively. So far 17892 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1337.85 on 09-Dec-2024 and a 52 week low of Rs. 541.00 on 02-Dec-2025.
Last one week high and low of the scrip stood at Rs. 578.40 and Rs. 541.00 respectively. The current market cap of the company is Rs. 20928.34 crore.
The promoters holding in the company stood at 57.49%, while Institutions and Non-Institutions held 27.34% and 15.17% respectively.
Cohance Lifesciences has received approval for the fund infusion by way of investment in compulsorily convertible preferred stock of NJ Bio Inc, USA, a subsidiary of the company, upto an amount of $10 million. The fund when deployed will be used by the said subsidiary to support its growth initiatives including capex.
The board of directors of the company in its meeting held on December 02, 2025 considered and approved the same.
Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization.
